By Chris Wack


Aurinia Pharmaceuticals Inc. said Tuesday it has entered into a settlement agreement with Indian pharmaceutical companies Sun Pharmaceutical Industries Inc., Sun Pharmaceuticals Industries Ltd. and Sun Pharma Global FZE.

The Canadian pharmaceuticals company said the settlement involves filing a joint motion with Sun Pharmaceutical to terminate an inter partes review of an Aurinia patent, as well as to settle patent infringement litigation in the U.S. over Sun Pharamceutical's Cequa dry-eye treatment.

Under the settlement, which is contingent upon the U.S. Patent Trial and Appeal Board approving the joint motion, the parties have agreed to dismiss their claims and counterclaims and cease bringing any future further legal action against each other.

Aurinia Pharmaceuticals shares were up 16% to $5.02 in premarket trading Tuesday.


Write to Chris Wack at chris.wack@wsj.com


(END) Dow Jones Newswires

01-03-23 0949ET